covid-19 recommendations vaccine

The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know

Reading now: 706
www.who.int

Updated 21 January 2022, pursuant to updated interim recommendations The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19.

This article provides a summary of those interim recommendations; you may access the full guidance document here.Here is what you need to know.According to SAGE, the Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective.

The priority is to start vaccinating health workers at high risk of exposure, followed by older adults, before immunizing the rest of the population. Who should be vaccinated first?While vaccine supplies are limited, it is recommended that priority be given to health workers at high risk of exposure and older people, including those aged 65 or older.Countries can refer to the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritization of target groups.Who else can take the vaccine?The vaccine has been found to be safe and effective in people with various conditions that are associated with increased risk of severe disease.This includes hypertension, diabetes, asthma, pulmonary, liver or kidney disease, as well as chronic infections that are stable and controlled.

Given the significant risk of severe COVID-19 for moderately or severely immunocompromised persons (ICPs), WHO advises an extended (3 dose) primary series based on available data, though individual safety monitoring is required, as is consultation with the treating physician.

Read more on who.int
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA